Aikang Medical (01789.HK) extended its strong performance today, with the stock price reaching HK$6.26 at the time of publication, up 7.75%, and a trading volume of approximately HK$62.787 million. The company’s recently released annual report highlighted the outstanding performance of its core business segment—orthopedic surgical robots—drawing market attention and driving sustained stock price growth.

(Image Source: uSMART HK app)

Solid Annual Results: Double-Digit Growth in Revenue and Profit

According to the financial report, Aikang Medical achieved revenue of RMB 1.482 billion in 2025, representing a year-on-year increase of 10.1%. Net profit attributable to equity shareholders was RMB 339 million, up 23.8% year-on-year. The improvement in profitability was primarily driven by revenue growth and enhanced gross margins from increased income from overseas and digital orthopedic customized products and services. Notably, sales revenue from orthopedic surgical robots grew over 200%, becoming a key driver of overall performance.

In terms of business structure, the contribution of digital orthopedics and customized services has become increasingly significant. By increasing the proportion of high-value-added products and optimizing the gross margin structure, the company has further strengthened overall profitability. Industry observers note that the rapid development of digital medical products, including orthopedic surgical robots and 3D-printed customized implants, provides long-term support for the company’s future revenue and profit growth.

International Market Expansion Shows Initial Success

Aikang Medical is actively promoting the “Aikang + JRI” dual-brand synergy strategy, offering orthopedic surgical robots and 3D-printed customized implants to overseas customers. The company has successfully sold three surgical robots internationally, with multiple overseas orders in the process of being signed. As the company’s brand influence grows in international markets, high-tech and high-value-added orthopedic products are expected to see substantial growth overseas.

Moreover, the overseas expansion not only drives revenue growth but also improves gross margin levels. Through a precise product portfolio and customized service strategy, the company is gradually establishing a competitive edge in international markets, which is expected to contribute significantly to steady future earnings growth.

Stock Performance Reflects Investor Confidence

Following the announcement, investors showed a positive response to Aikang Medical’s orthopedic surgical robots and digital orthopedic business prospects. The stock continued to rise in early trading with active transactions, indicating market recognition of the company’s high-growth business. Industry observers believe that as orthopedic surgical robot technology matures and overseas orders are gradually fulfilled, the company’s competitiveness in the medical device sector will further strengthen.

Overall, leveraging innovative products, high-end customized services, and international market expansion, Aikang Medical is forming a new engine for growth. The market remains attentive to the company’s potential in digital and smart orthopedics, which is expected to continue supporting the stock’s performance.

How to Buy Aikang Medical via on uSMART

After logging into the uSMART HK app, click the “Search” button in the top-right corner of the page, enter the ticker code(01789.HK), and navigate to the details page to view transaction details and historical trends. Click the “Trade” button in the bottom-right corner, select the trade type, and submit your order after filling in the transaction conditions.

(Image Source: uSMART HK app)